Owlet Announces CEO Transition; Board Reaffirms Q1 2026 Guidance and Long-Term Growth Opportunity

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

LEHI, Utah--(BUSINESS WIRE)-- Owlet, Inc. (“Owlet” or the “Company”) (NYSE: OWLT), the pioneer of smart infant monitoring, announced today that Jonathan Harris has resigned as President and Chief Executive Officer, effective immediately. The Board thanks Jonathan for his leadership and dedicated service to the Company and families worldwide.

Kurt Workman, current Executive Chair of the Board, co-founder, and former CEO, will rejoin as President and Chief Executive Officer to lead the Company and execution of its strategic priorities. Kurt will cease serving as Executive Chairman of the Board, but will remain a director of the Board.

“I’m incredibly excited to have Kurt back in the CEO role. His strategic vision for the future of Owlet and his demonstrated ability to effectively execute on that vision make him uniquely qualified for the CEO role as we enter this next chapter of the business. The Board and I welcome his energy and commitment to leading the Owlet team as we solidify our leadership position as partners to the next generation of families, globally,” said Lior Susan, Owlet’s Chairman of the Board.

Financial Update

• Owlet expects to be at the high end of its Q1 2026 revenue guidance range.
• Owlet will report Q1 2026 financial results and business outlook in early May 2026. The Company remains committed to profitability, driven by revenue growth, continued expense discipline, and a focus on operational excellence.
• Owlet reaffirms its long-term strategic pillars of increasing adoption, expanding LTV, and leveraging Owlet’s vast and growing data set to create the pediatric health platform parents need for their children.
• Reinforcing this commitment to the Company’s long-term plan, Owlet also announced today that Chief Financial Officer, Amanda Twede Crawford, has elected to receive 100% of her 2025 annual bonus in Owlet common stock in lieu of cash.

“My return as CEO is a commitment to the mission I started in a garage 12 years ago,” said Kurt Workman. “Owlet is the category leader in pediatric health monitoring with an unparalleled data set, yet there is still an immense opportunity to increase our market penetration, accelerate adoption and improve the health and wellness of infants worldwide. I am stepping back in to deliver on this vision. My goal is to make Owlet the standard for at-home pediatric health, and I’m ready to get back to work with this incredible team, our amazing partners and the parents around the world that put their faith and trust in the Owlet brand.”

Financial Disclosure Advisory

This press release contains certain estimated preliminary financial results for the first quarter ended March 31, 2026. These estimates are based on the information available to the Company at this time. The Company’s financial closing and procedures for the first quarter of fiscal 2026 are not yet complete and, as a result, actual results may vary from the estimated preliminary results presented here. The estimated preliminary financial results have not been audited or reviewed by the Company’s independent registered public accounting firm. These estimates should not be viewed as a substitute for the Company’s full interim financial statements. Accordingly, you should not place undue reliance on this preliminary financial information.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the “Reform Act”). All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding the Company's expected financial performance, including the Company's financial outlook and reaffirmation of previously issued guidance, the anticipated benefits of the Company's leadership transition, the Company's long-term strategic priorities and business strategy, including plans related to market penetration, user growth and scaling of the Company's subscription model, leveraging the Company's data to build its pediatric health platform, product enhancements, growth prospects, future operational results, and expected market opportunity and acceptance. In some cases, you can identify forward-looking statements by terms such as “estimate,” “may,” “believes,” “plans,” “expects,” “anticipates,” “intends,” “goal,” “potential,” “upcoming,” “outlook,” “guidance,” the negation thereof, or similar expressions, although not all forward-looking statements contain these identifying words. Forward-looking statements are based on the Company’s expectations at the time such statements are made, speak only as of the dates they are made and are susceptible to a number of risks, uncertainties and other factors. Many important factors could affect the Company’s future results and cause those results to differ materially from those expressed in or implied by the Company’s forward-looking statements. Such factors include, but are not limited to, (i) the regulatory pathway for Owlet’s products, including submissions to, actions taken by and decisions and responses from regulators, such as the FDA and similar regulators outside of the United States, as well as Owlet’s ability to obtain and maintain regulatory approval or certification for our products and other regulatory requirements and legal proceedings; (ii) Owlet’s competition and the Company’s ability to achieve future growth and sustain its growth rate; (iii) Owlet’s ability to attract and retain customers and increase sales to its customers; and (iv) other risks and uncertainties set forth in the Company’s other releases, public statements and filings with the U.S. Securities and Exchange Commission (“SEC”), including those identified in the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, as any such factors may be updated from time to time in the Company’s other filings with the SEC. Except as required by law, the Company assumes no obligation to update any forward-looking statements after the date of this press release, whether because of new information, future events or otherwise, although Owlet may do so from time to time. The Company does not endorse any projections regarding future performance that may be made by third parties.

About Owlet, Inc.

Owlet, Inc. (NYSE: OWLT), a leading pediatric health platform, is the only company in the world to offer U.S. FDA-cleared and internationally medically-certified wearable pediatric monitors, delivering hospital-grade technology directly in the home. Our award-winning pediatric products and innovative software combine clinically tested monitoring systems, an integrated video platform, and a simple, easy-to-use app, providing parents with real-time health insights to stay informed on their child’s well-being, support restful sleep, and provide peace of mind anywhere. Since 2012, more than 2.5 million parents have trusted Owlet to monitor their children's well-being and sleep. This adoption has fueled one of the largest collections of pediatric health and sleep data in the world, powering innovations that bridge the critical gap between hospital and home. Owlet is driving a new standard in pediatric wellness by pairing advanced medical technology with consumer-friendly design. Our mission is simple yet ambitious: to give every baby and every family the best possible start in life. Learn more at www.owletcare.com and follow us on LinkedIn and Instagram for company news and updates.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260406627177/en/

Owlet Media Contacts:
pr@owletcare.com
owlet@hannahcranstonmedia.com

Owlet Investor Contact:
ir@owletcare.com

Source: Owlet, Inc.